News/ News/ Oncology ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma Phil Taylor ASCO 2022, BCMA, bispecific, elranatamab, Johnson & Johnson, multiple myeloma, Pfizer, teclistamab 0 Comment Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or Share X ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma https://pharmaphorum.com/news/asco22-jj-pfizer-trade-bcma-bispecific-data-in-myeloma/